首页 | 本学科首页   官方微博 | 高级检索  
检索        

血塞通软胶囊联合比索洛尔治疗2型糖尿病合并左室舒张功能减退临床观察
引用本文:李云倩,魏伟平,全会标.血塞通软胶囊联合比索洛尔治疗2型糖尿病合并左室舒张功能减退临床观察[J].中华中医药学刊,2020(2):222-226.
作者姓名:李云倩  魏伟平  全会标
作者单位:;1.海南省人民医院
基金项目:海南省科技厅项目(ZDXM20120046)。
摘    要:目的探讨血塞通软胶囊联合比索洛尔治疗2型糖尿病合并左室舒张功能减退的临床效果。方法选择2017年8月-2018年8月治疗的2型糖尿病合并左室舒张功能减退的患者120例,依据随机数字的方法分为对照组(60例)和观察组(60例),患者入院后均常规治疗,对照组在常规治疗基础上给予比索洛尔,观察组在对照组治疗方法基础上给予血塞通软胶囊。对两组治疗前后的空腹血糖(FPG),餐后2 h血糖(2hPG),糖化血红蛋白(HbA1c),E波峰值流速/A波峰值流速(E/A),E峰减速时间(EDT),左心室容舒张时间(IVRT),血清B型尿钠肽(BNP)浓度进行比较。对两组的治疗效果进行比较。对治疗过程中的不良反应进行对比。结果经过治疗后,对照组的FPG从(7.85±0.67)mmol/L降低到(6.45±0.48)mmol/L,2 hPG从(12.21±1.23)mmol/L降低到(9.35±1.45)mmol/L,HbA1c从(9.31±0.95)%降低到(8.22±0.68)%,观察组的FPG从(7.89±0.71)mmol/L降低到(5.88±0.23)mmol/L,2hPG从(12.37±1.35)mmol/L降低到(8.27±1.34)mmol/L,HbA1c从(9.38±0.88)%降低到(7.14±0.71)%,观察组的变化幅度大于对照组,数据差异均具有统计学意义(t=8.295,4.237,8.509,P<0.05),经过治疗后,对照组的E/A从(0.83±0.13)升高到(0.98±0.17),EDT从(80.51±5.47)ms升高到(92.81±6.23)ms,IVRT从(121.48±7.79)ms升高到(131.51±7.66)ms,观察组的E/A从(0.84±0.12)升高到(1.18±0.21),EDT从(81.65±5.67)ms升高到(98.57±6.72)ms,IVRT从(120.98±7.81)ms升高到(139.25±6.81)ms,观察组的变化幅度大于对照组,数据差异均具有统计学意义(t=-5.734,-4.869,-5.849,P<0.05),经过治疗后,对照组的血清BNP浓度从(222.56±43.25)ng/L降低到(167.11±27.61)ng/L,观察组的血清BNP浓度从(228.92±44.91)ng/L降低到(131.25±25.07)ng/L,观察组的变化幅度大于对照组,数据差异均具有统计学意义(t=7.448,P<0.05),观察组治疗效果优于对照组,数据差异具有统计学意义(z=-2.184,P<0.05),两组的头晕8.33%(5/60)vs.5.00%(3/60)],水肿3.33%(2/60)vs.6.67%(4/60)],面部潮红11.67%(7/60)vs.8.33%(5/60)],头痛5.00%(3/60)vs.1.67%(1/60)],发生率数据差异均不具有统计学意义(χ^2=0.134,0.175,0.370,0.259,P>0.05)。结论利用血塞通软胶囊联合比索洛尔治疗2型糖尿病合并左室舒张功能减退的患者,可以改善血糖指标和心室功能指标,提升治疗效果,安全性良好。

关 键 词:血塞通软胶囊  比索洛尔  2型糖尿病  左室舒张功能减退

Clinical Observation of Xuesaitong Soft Capsule Combined with Bisoprolol in Treatment of Type 2 Diabetes with Left Ventricular Diastolic Function
LI Yunqian,WEI Weiping,QUAN Huibiao.Clinical Observation of Xuesaitong Soft Capsule Combined with Bisoprolol in Treatment of Type 2 Diabetes with Left Ventricular Diastolic Function[J].Chinese Archives of Traditional Chinese Medicine,2020(2):222-226.
Authors:LI Yunqian  WEI Weiping  QUAN Huibiao
Institution:(Hainan Provincial People’s Hospital,Haikou 570311,Hainan,China)
Abstract:Objective To explore the clinical effect of Xuesaitong Soft Capsule combined with bisoprolol in the treatment of type 2 diabetes with left ventricular diastolic dysfunction.Methods A total of 120 patients with type 2 diabetes mellitus complicated with left ventricular diastolic dysfunction who were treated from August 2017 to August 2018 were enrolled.According to the method of random number,they were divided into control group(n=60)and observation group(n=60).The patients were routinely treated after admission.The patients in the control group were given bisoprolol on the basis of conventional treatment.The patients in the observation group were given Xuesaitong Soft Capsule on the basis of the treatment method of the control group.Fasting blood glucose(FPG)before and after treatment in both groups,2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1 c),E wave peak flow rate/A wave peak flow rate(E/A),E peak deceleration time(EDT),Left ventricular diastolic time(IVRT)and serum B-type natriuretic peptid(BNP)concentrations were compared.The treatment effects of the two groups were compared.The adverse reactions during treatment were compared.Results After treatment,the FPG of the control group decreased from(7.85±0.67)mmol/L to(6.45±0.48)mmol/L,and the 2 hPG decreased from(12.21±1.23)mmol/L to(9.35±1.45)mmol/L.HbA1 c decreased from(9.31±0.95)%to(8.22±0.68)%.The FPG of the observation group decreased from(7.89±0.71)mmol/L to(5.88±0.23)mmol/L,and the 2 hPG decreased from(12.37±1.35)mmol/L to(8.27±1.34)mmol/L,and HbA1 c decreased from(9.38±0.88)%to(7.14±0.71)%.The change of the observation group was larger than that of the control group,and the data was statistically significant(t=8.295,4.237,8.509,P<0.05).After treatment,the E/A of the control group increased from(0.83±0.13)to(0.98±0.17),and the EDT increased from(80.51±5.47)ms to(92.81±6.23)ms,IVRT increased from(121.48±7.79)ms to(131.51±7.66)ms.The E/A of the observation group increased from 0.84±0.12 to 1.18±0.21,EDT increased from(81.65±5.67)ms to(98.57±6.72)ms,and IVRT increased from(120.98±7.81)ms to(139.25±6.81)ms.The change of the observation group was larger than that of the control group,and the data was statistically significant(t=-5.734,-4.869,-5.88,P<0.05).After treatment,the serum BNP concentration of the control group decreased from(222.56±43.25)ng/L to(167.11±27.61)ng/L.Serum BNP concentrations in the observation group decreased from(228.92±44.91)ng/L to(131.25±25.07)ng/L.The change of the observation group was larger than that of the control group,and the data was statistically significant(t=7.448,P<0.05).The therapeutic effect of the observation group was better than that of the control group,and the data was statistically significant(z=-2.184,P<0.05).the incidence of dizziness8.33%(5/60)vs.5.00%(3/60)],edema3.33%(2/60)vs.6.67%(4/60)],facial flushing11.67%(7/60)vs.8.33%(5/60)],headache5.00%(3/60)vs.1.67%(1/60)]in both groups was not statistically significant(χ^2=0.134,0.175,0.370,0.259,P>0.05).Conclusion Using Xuesaitong Soft Capsule combined with bisoprolol in patients with type 2 diabetes mellitus complicated with left ventricular diastolic dysfunction can improve blood glucose index,ventricular function index and treatment effect,and has good safety.
Keywords:Xuesaitong Soft Capsule  bisoprolol  type 2 diabetes  left ventricular diastolic dysfunction
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号